RI H8245

Requires health insurers to provide reimbursement for up to 365 days of prescription hormone therapy dispensed at one time, beginning with plan years after January 1, 2027

Defines prescription hormone therapy as FDA-approved drugs used to suppress, increase, or replace hormones, including necessary administration supplies, but explicitly excludes GLP-1 and GLP-1 receptor agonists (weight loss medications)

Applies to individual and group health plans, nonprofit hospital and medical service corporations, HMOs, and Medicaid beneficiaries

Allows smaller supplies if requested by the enrollee or prescribed provider, or if the medication is a controlled substance (limited to maximum refill allowed by law)

Requires the Executive Office of Health and Human Services to submit a Medicaid state plan amendment within 90 days of the act's effective date